History of Pneumococcal Immunization

作者: P. Helena Mäkelä , Jay C. Butler

DOI: 10.1128/9781555815820.CH2

关键词:

摘要: By the year 1800, 200 years ago, smallpox vaccine had established principle of preventing serious disease by active immunization. In 1940s, these whole-cell vaccines were supplanted next generation pneumococcal vaccines, which consisted purified capsular polysaccharides (PS) bacteria. As early as 1891, animal experiments showed that killed pneumococci elicited protective immunity to subsequent challenge with virulent The influenza pandemic 1918 1919, together First World War, created a situation conducive highly increased incidence pneumonia. Researchers administered trivalent 12,519 men in training at United States. results trials considered very encouraging time. Even 30% reduction numbers cases lobar pneumonia was welcomed because there no alternative prevention measures. experimental research Avery, Heidelberger, and Goebel 1920s formed essential links between capsules, their serotype specificity, identity capsules PS could be isolated from bacterial cultures chemical means. Despite recommendations for routine immunization at-risk populations, uptake relatively slow. Nearly 10 after licensure States, only 10% persons whom recommended ever been immunized. Protection against bacteremia, provided 23-valent vaccine, wanes over period 3 5 years, particularly older people.

参考文章(77)
Charlene E. Bush, Richard M. Donovan, Norman P. Markowitz, Paul Kvale, Louis D. Saravolatz, A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. Journal of Acquired Immune Deficiency Syndromes. ,vol. 13, pp. 23- 26 ,(1996) , 10.1097/00042560-199609000-00004
D. Fedson, J. Henrichsen, P. H. Mäkelä, R. Austrian, Immunization of elderly people with polyvalent pneumococcal vaccine. Infection. ,vol. 17, pp. 437- 441 ,(1989) , 10.1007/BF01645568
I.D. Riley, M. Andrews, R. Howard, P.I. Tarr, M. Pfeiffer, P. Challands, G. Jennison, R.M. Douglas, IMMUNISATION WITH A POLYVALENT PNEUMOCOCCAL VACCINE: Reduction of Adult Respiratory Mortality in a New Guinea Highlands Community The Lancet. ,vol. 309, pp. 1338- 1341 ,(1977) , 10.1016/S0140-6736(77)92552-1
William H. Park, Anna I. von Sholly, VII. Report on the Prophylactic Vaccination of 1536 Persons Against Acute Respiratory Diseases, 1919–1920 Journal of Immunology. ,vol. 6, pp. 103- 115 ,(1921)
G Zon, S C Szu, W Egan, J D Robbins, J B Robbins, Hydrolytic stability of pneumococcal group 6 (type 6A and 6B) capsular polysaccharides. Infection and Immunity. ,vol. 37, pp. 89- 103 ,(1982) , 10.1128/IAI.37.1.89-103.1982
Alicia M Fry, Elizabeth R Zell, Anne Schuchat, Jay C Butler, Cynthia G Whitney, Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine. ,vol. 21, pp. 303- 311 ,(2002) , 10.1016/S0264-410X(02)00451-6
WALTER W. WILLIAMS, Immunization Policies and Vaccine Coverage Among Adults Annals of Internal Medicine. ,vol. 108, pp. 616- 625 ,(1988) , 10.7326/0003-4819-108-4-616
Colin M. MacLeod, Richard G. Hodges, Michael Heidelberger, William G. Bernhard, PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES Journal of Experimental Medicine. ,vol. 82, pp. 445- 465 ,(1945) , 10.1084/JEM.82.6.445